FDA
-
-
-
-
-
-
-
Hansa Biopharma publishes 2025 Annual and Sustainability Reports
-
-
-
-
-
-
-
Hansa Biopharma's imlifidase meets primary endpoint in Phase 3 kidney trial
-
-
-
-
-
-
-
Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease
-
-
-
-
-
-
-
Hansa Biopharma half year report 2023
-
-
-
-
-
-
-
Hansa Biopharma: Notice to Annual General Meeting
-
-
-
-
-
-
-
Hansa Biopharma interim report Jan-Sept 2021
-
-
-
-
-
-
-
Hansa Biopharma Interim Report Jan-Jun 2020
-
328,997 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

